IV Opdivo Approved in Taiwan in Combination with Cisplatin & Gemcitabine for the 1L Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma October 15, 2024
First Patient Dosed in Ph 3 Clinical Trial of UGN-103 in patients with Low-Grade Intermediate-Risk NMIBC October 8, 2024
ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in OS compared to enzalutamide in patients with mCSPC October 8, 2024
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in RCC October 8, 2024
Supplemental NDA submitted to FDA for darolutamide + ADT combo in patients with mHSPC October 1, 2024
KEYTRUDA Receives New Approvals in Japan for perioperative Patients With NSCLC and in Radically Unresectable Urothelial Carcinoma October 1, 2024
Ph 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study Announced September 24, 2024
Trials evaluating ONCT-534 in metastatic CRPC & ONCT-808 in BCL discontinued to explore strategic alternative September 18, 2024
GI Innovation Announces New Clinical Trial Collaboration and Supply Agreement to Evaluate GI-102 + KEYTRUDA in Patients with IO-Resistant HCC, Melanoma, and RCC September 3, 2024
CDE of NMPA Approves to Initiate Ph 3 Trial of 9MW2821 for Urothelial Carcinoma in Combination with PD-1 Inhibitor September 3, 2024
European Commission Approves PADCEV (enfortumab vedotin) + KEYTRUDA (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer September 3, 2024
European Commission approves BALVERSA (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma August 27, 2024
Vobramitamab Duocarmazine Update Provided; treatment recently discontinued for TAMARACK metastatic CRPC patients who remained eligible for further dosing August 7, 2024
Positive EU CHMP Opinion for KEYTRUDA + Padcev as 1L Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma July 30, 2024
Darolutamide meets primary endpoint in Ph 3 ARANOTE trial in men with metastatic hormone-sensitive prostate cancer July 23, 2024
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations for Evaluating ORIC-944 + AR Inhibitors for the Treatment of Prostate Cancer July 23, 2024
FAILED TRIAL: Ph 3 TiNivo-2 didn’t meet primary endpoint from rechallenging RCC patients with immunotherapy after receiving ICI beyond progression on previous ICIs July 23, 2024
Positive Interim Ph 2 Monotherapy Expansion Data for IDE397 in MTAP-Deletion Urothelial and Lung Cancer Announced July 17, 2024
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat for the Treatment of Metastatic CRPC July 9, 2024
Ubix Therapeutics and Yuhan Announce Exclusive License Agreement for UBX-103 for Treatment of Metastatic CRPC July 9, 2024
